---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-015514"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:45:08.122593+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Puma swings to Q1 profit; NERLYNX revenue up 7% to $43.1M

## Summary
- GAAP net income $3.0M ($0.06 EPS) vs net loss $4.8M ($0.10 loss) in Q1 2024.
- Non-GAAP adjusted net income $5.0M ($0.10 EPS) vs adjusted loss $2.4M.
- Product revenue $43.1M (+7% YoY), royalty revenue $2.9M.
- Q2 2025 guidance: net product revenue $48-50M, net income $4-6M.
- Cash & securities $93.2M at Mar 31, down from $101.0M at Dec 31.

## SEC filing metadata
- accession: 0001437749-25-015514
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774925015514/0001437749-25-015514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774925015514/pbyi20250303_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-015514
- JSON: https://secwatch.observer/filing/0001437749-25-015514.json
- Plain text: https://secwatch.observer/filing/0001437749-25-015514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.